Are there data for treating patients with metastatic NSCLC with BRAF nonV600E mutations with BRAF and MEK inhibitors?

There is limited data on the efficacy of RAF and MEK inhibitors in the treatment of patients with lung adenocarcinoma that harbor a BRAF non-V600E mutation. Published series of small numbers of patients suggest that Dabrafenib, Vemurafenib, and Trametinib are less active in this patient population c...

Braf inhibitors were less effective in this patient population compared to those whose tumors harbor BRAF V600E mutations in the two main studies that focused on Braf NSCLC.